Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates

Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).
The collaboration will utilize Adare’s proprietary modified-release technologies. The enhanced collaborative formulations are intended to deliver an effective pharmacokinetic profile, and are expected to improve patient compliance and disease management. MZD is a norepinephrine reuptake inhibitor previously approved by the US FDA for the treatment of obesity.

“We are excited to enter this collaboration with NLS to develop new formulations for MZD, which will provide enhanced patient centric solutions for central nervous system disorders,” said Ajay Damani, Vice President, Pharmaceutical Technologies of Adare. “Our expertise with product development and manufacturing of customized release and multiparticulate dosage forms makes this an ideal partnership for Adare.”

“We believe that the partnership with Adare provides us with the expertise with respect to formulation that may help us to efficiently develop our product candidates. We value the experience Adare offers as part of our supply chain, and the new intellectual property applied to our product candidates. We anticipate success for both parties in this collaboration,” said Alex Zwyer, CEO and co-founder of NLS.

Adare Pharmaceuticals utilizes its differentiated Pharmaceutical Technology and Microbiome scientific platforms to develop novel value-added products for the global market. Through its Specialty CDMO business, Adare provides co-development and contract services to biopharmaceutical companies to develop and manufacture products that are marketed by its partners. Through its Adare Development affiliate, Adare invests in its own product pipeline and currently has a number of investigational products in various stages of development, including APT-1011. Adare has developed and manufactured more than 40 products sold by partners in more than 100 countries globally including Lacteol, Zoolac, Viactiv, and a number of branded and complex generic products. For more information, visit

NLS Pharmaceutics Ltd. is a privately owned, Swiss-based biopharmaceutical company engaged in the discovery and development of novel, life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders. NLS is building a pipeline of product candidates at various stages of development led by a team with significant industry experience and a successful track record. NLS’ lead compound, mazindol controlled release, has received Orphan Drug Designation both in the US and in Europe for treating narcolepsy and has completed a phase 2 study in the U.S. in adult subjects with ADHD demonstrating best-in-class efficacy and a favorable safety profile.
For more information, visit